Expression of the Epstein ± Barr virus (EBV) transforming LMP1 in B cells activates the transcription factor NF-kB and induces phenotypic changes through two distinct domains in the cytoplasmic C-terminus of the protein. The aa 187 ± 231 domain of LMP1, which is important for growth transformation, binds tumour necrosis factor (TNF) receptor associated factor (TRAF) 1 and TRAF3 and this interaction mediates subsequent signalling events. The TRAFs also associate with CD40, a member of the TNFR family, which upon ligation activates NF-kB and induces phenotypic changes similar to those mediated by LMP1. This study demonstrates that LMP1 expression in carcinoma cell lines and SV40-transformed keratinocytes results in induction of the pleiotropic cytokine interleukin 6 (IL6), an eect which is also observed upon CD40 ligation. The mechanism by which either LMP1 expression or CD40 ligation induces IL6 production was found to be NF-kB-dependent. Mutational analysis identi®ed domains in the C-terminus of LMP1 which are important for NF-kB activation and IL6 secretion. LMP1 and CD40 share a common PxQxT core TRAF binding motif and mutations in or adjacent to this sequence impaired the ability of LMP1 or CD40 to induce NF-kB activation and IL6 secretion. The importance of TRAF interactions in mediating these eects was con®rmed using dominant negative TRAF2 and TRAF3 mutants which also identi®ed dierences in the signalling events mediated by the two NF-kB activating domains of LMP1. A20, an anti-apoptotic protein which interacts with TRAF2 and blocks CD40-mediated NF-kB activity, also blocked NF-kB and IL6 secretion in LMP1-transfected epithelial cells. These results suggest that LMP1 regulates IL6 production in epithelial cells in a manner similar to CD40 ligation and implicate TRAFs as common mediators in the transduction of signals generated via the CD40 and LMP1 pathways. As a role for IL6 in regulating epithelial cell growth has previously been suggested, the control of IL6 secretion via the CD40 and LMP1 pathways may have implications for the growth of both normal and transformed epithelial cells.
Introduction
Epstein ± Barr virus (EBV) is a human herpesvirus associated with a number of malignancies including Burkitt's lymphoma, undierentiated nasopharyngeal carcinoma (NPC), B-cell lymphoma in immunodeficient patients and Hodgkin's disease (Young and Rowe, 1992) . EBV infection transforms resting B lymphocytes in vitro resulting in the outgrowth of immortalized lymphoblastoid cell lines (LCLs). Among the nuclear and integral membrane proteins expressed in LCLs, the nuclear antigens EBNA2, EBNA3A and EBNA3C and the latent membrane protein 1 (LMP1) are essential for growth transformation and immortalization (Liebowitz and Kie, 1993; Henderson et al., 1994) . LMP1 is of particular interest as it resembles a classical oncogene in its ability to induce growth transformation of certain rodent ®broblast cell lines (Wang et al., 1985; Baichwal and Sugden, 1988) . In addition, expression of this viral oncogene in the absence of other EBV genes in B-cell lines can induce many of the phenotypic changes reminiscent of the activation process initiated by EBV infection, including up-regulation of CD23, CD40 and CD54 (ICAM1) (Wang et al., 1988 (Wang et al., , 1990 Huen et al., 1995) . LMP1 expression in epithelial cells also results in induction of CD40 and CD54 expression and blocks dierentiation, a property which may be important in the pathogenesis of NPC (Young et al., 1988; Dawson et al., 1990; Dawson, Eliopoulos and Young, unpublished observations) . Recent studies have suggested that LMP1 can confer growth inhibitory eects in EBV-negative Burkitt lymphoma cells and in tumour cell lines of epithelial origin Eliopoulos et al., 1996) .
In resting B-cells signalling through CD40, a 50 kDa glycoprotein belonging to the tumour necrosis factor receptor (TNF-R) superfamily, stimulates cell survival, growth and dierentiation (Stamenkovic et al., 1989; Banchereau et al., 1994; Clark and Ledbetter, 1994; Gordon, 1995) . The ligand for CD40 (CD40L) is a 39 kDa membrane protein with homology to TNF, which can be induced on T cells following their activation via the T cell receptor (Armitage et al., 1992; Lederman et al., 1992; Noelle et al., 1992) . Recent studies indicate a central role for CD40/CD40L in the regulation of humoral immunity and host defence (Noelle, 1996) . CD40 ligation in B cells induces a number of phenotypic changes similar to those observed upon LMP1 expression, including upregulation of CD23 and CD54 and induction of homotypic cell adhesion. In addition, both LMP1 and CD40 signalling result in up-regulation of the expression of certain anti-apoptotic proteins, such as A20 and members of the bcl-2 family, which may at least partly account for the survival advantage confered by CD40 engagement or LMP1 expression in normal B-cells (Henderson et al., 1991; Laherty et al., 1992; Rowe et al., 1994; Choi et al., 1995; Sarma et al., 1995) . Studies from our and other laboratories have shown that CD40 is not only expressed in lymphoid cells but it is also present in normal, basal epithelial cells and in a number of carcinomas including ovarian, nasopharyngeal, bladder and breast (Stamenkovic et al., 1989; Young et al., 1989; Banchereau et al., 1994; Gallagher et al., manuscript in preparation) , where its role remains widely unknown. We have recently shown that CD40 ligation in keratinocytes and a number of tumour epithelial cell lines induces growth inhibition, an eect which is also observed following expression of LMP1 (Eliopoulos et al., 1996) .
Similarities between the eects of CD40 and LMP1 signalling suggest that common biochemical pathways may be activated by these molecules. A number of proteins with homology to TNF receptor-associated factors (TRAFs) have been recently identi®ed and these appear to be important in mediating LMP1 and CD40 signalling. Thus, TRAF2 and TRAF3 (also named CD40bp, CRAF1, CAP1 or LAP1) associated with the cytoplasmic C-terminus domains of both LMP1 and CD40 through a PxQxT/S domain, whilst TRAF1 interacts directly with LMP1 but not with CD40 (Hu et al., 1994; Mosialos et al., 1995; Sato et al., 1995; Devergne et al., 1996; Cheng and Baltimore, 1996) . TRAF3 has been implicated in CD40-mediated up-regulation of CD23 in Ramos B cells and TRAF2 has been shown to mediate activation of the transcription factor NF-kB upon engagement of CD40, TNFRI or TNFRII by an as yet unknown mechanism (Rothe et al., 1995; Hsu et al., 1996) . LMP1 expression can also activate the transcription factor NF-kB through two distinct domains in its cytoplasmic C-terminus and this eect is clearly responsible for some of the phenotypic consequences of activation through LMP1 Huen et al., 1995; Mitchell and Sudgen, 1995) .
Recent data suggest that the gene encoding for interleukin 6 (IL6) is regulated by NF-kB. IL6 is a cytokine with pleiotropic activities and has been shown to play a central role in immune host-defence mechanisms by perpetuating an in¯ammatory response (Akira et al., 1993) . Important functions of IL6 include up-regulation of ICAM1 (CD54), an adhesion molecule mediating immune and inflammatory responses (Hutchins and Steel, 1994) , induction of dierentiation of certain haemopoietic cell lines and growth inhibition or stimulation depending on the nature of the responsive target cell (Kawano et al., 1988; Chen et al., 1991; Takizawa et al., 1993) . IL6 has also been shown to be an important co-stimulatory molecule for primary generation of antitumour cytolytic T lymphocytes in vitro (Gajewski et al., 1995) and an essential co-factor for CD40-induced isotype switching (Jabara et al., 1990) . The IL6 promoter contains NF-kB sites and is under dominant control by this transcription factor following TNF treatment (Libermann and Baltimore, 1990; Shimizu et al., 1990) . CD40 has also been shown to mediate IL6 secretion (Clark & Shu, 1990; Hess et al., 1995; Yellin et al., 1995) , however the molecular events leading to this eect are unclear.
This study demonstrates that LMP1 expression in human carcinoma cell lines and SV40-transformed keratinocytes induces IL6 production via an NF-kB mechanism. This eect is mimicked by CD40 ligation and is mediated by distinct domains in the cytoplasmic C-terminus of LMP1 and CD40. TRAF molecules regulate NF-kB activity and IL6 secretion from these domains, suggesting that despite the lack of structural similarities, LMP1 and CD40 share not only common functions but also overlapping signalling pathways.
Results
Tumour epithelial cell lines stably transfected with LMP1 secrete elevated levels of IL6
HeLa cervical carcinoma cells were transfected with the pSV2.gpt.MTLM plasmid which directs expression of LMP1 from an inducible metallothionein promoter and stable clones resistant to mycophenolic acid were obtained. As the metallothionein-inducible system is not tightly regulated, basal LMP1 expression was seen in two HeLa/LMP1 clones examined (HeLa.LMP1 cl.1 and cl.2) in the absence of induction by heavy metals (Figure 1a) . Examination of these stable transfectants for secretion of IL6 revealed that the LMP1-expressing cells secrete 16 ± 18-fold more IL6 than the parental or vector-transfected cells (Figure 1b) . Interestingly, the HeLa/LMP1 transfectants also exhibited higher constitutive levels of NF-kB than the control cells, as determined by luciferase reporter assays. Thus, transfection of an NF-kB-dependent promoter luciferase reporter plasmid (kBconA-Luc) into LMP1-expressing HeLa cells demonstrated that the LMP1 clones expressed approximately 4 ± 7-fold higher NFkB activity than control cells (Figure 1b) .
In order to determine the speci®city of the LMP1 eect on IL6, HeLa/LMP1 cl.1 and cl.2 cells were induced to express high levels of LMP1 by treatment with 6 mM cadmium chloride (CdCl 2 , Figure 1c ). This concentration of CdCl 2 was selected on the basis of optimal induction of LMP1 and lack of cellular toxicity during a 24 ± 72 h time-period. Induction of LMP1 following exposure of HeLa/LMP1 cl.1 and cl.2 cells to cadmium occurred within 6 h and was maximal at 24 h post-treatment ( Figure 1c and data not shown). In these experiments, induction of LMP1 in HeLa cells increased IL6 secretion by 3 ± 5-fold when compared to untreated LMP1 clones (Figure 1d ). IL6 levels in control cultures remained unaected. Similar increases in IL6 were observed in pSV2.gpt.MTLM-transfected EJ bladder, A2780 ovarian and SCC12F squamous cell carcinoma cells.
Transient LMP1 expression induces IL6 production in tumour epithelial cell lines via an NF-kB mechanism As stable LMP1 expression was found to induce activation of NF-kB and IL6 secretion in epithelial tumour cell lines, the eect of transient LMP1 expression on the SV40-transformed keratinocyte cell line SV-AR-K and in a number of other epithelial cell lines was determined. Transfection of pSG5-LMP1, a SV40 early promoter-driven LMP1-expression vector, in SV-AR-K cells produced high levels of LMP1 expression which peaked at 36 ± 48 h post-transfection (See Figure 5b and data not shown). Immunofluorescence staining for LMP1 expression showed that a 25 ± 35% transfection eciency was routinely obtained. Transient LMP1 expression was found to induce a time-dependent activation of NF-kB, as assessed by both luciferase and electrophoretic mobility shift assays (EMSAs). Thus, co-transfection of SV-AR-K cells with pSG5-LMP1 and kB-conA-Luc plasmids showed that luciferase synthesis paralleled LMP1 expression, demonstrating a maximal 37-fold increase in NF-kB activity at 48 h post-transfection (Figure 2a ). The speci®city of this reporter assay for NF-kB activation was con®rmed in control co-transfection experiments in which LMP1 expression failed to induce luciferase synthesis from a ConA-Luc plasmid lacking the kBsites. Similar results were obtained with an HIV-LTR luciferase reporter gene construct but not with its mutated version containing inactivated NF-kB sites. Induction of NF-kB binding activity in response to transient LMP1 expression was veri®ed by EMSAs using a 32 P-labelled HIV-kB probe. Thus, transfection of pSG5-LMP1 in SV-AR-K cells increased binding of NF-kB in a time-dependent manner ( Figure 2b , left panel) and this eect was not seen using an HIV-kB probe with mutated kB sites (data not shown). Supershift experiments using antibodies against the p50 and p65 units of NF-kB showed that the NF-kB complex activated by LMP1 contains p50 : p65 heterodimers ( Figure 2b , right panel). The speci®city of the DNA binding was assessed by competition experiments using a 50-fold excess of non-radioactive HIV-kB probe ( Figure 2b , right panel).
In order to determine whether LMP1 can activate IL6 at the transcriptional level, RNA isolated from SV-AR-K cells at various time points post-transfection with pSG5-LMP1 was subjected to semiquantitative RT ± PCR using primers speci®c for IL6 and using GADPH as an internal control. These experiments showed that IL6 mRNA levels increased in parallel with expression of LMP1 and activation of NF-kB, demonstrating a maximum of approximately 3.3-fold increase in IL6 transcription at 48 h post-transfection (Figure 2c, left panel) . Supernatants from LMP1-transfected or control vector-transfected SV-AR-K cells were subsequently examined for levels of secreted IL6 protein by using an IL6-speci®c ELISA. In accordance with the RT ± PCR data, a signi®cant, time-dependent increase in IL6 secretion was observed in the LMP1 but not in vector-transfected SV-AR-K cells (Figure 2c, 
expression of LMP1 in these cell lines resulted in 12 ± 32-fold increase in NF-kB transcriptional activity and a 10 ± 40-fold increase in IL6 secretion depending on the cell type and the transfection eciency (data not shown). These eects were speci®c for LMP1 as overexpression of LMP2A or LMP2B, other EBV-encoded latent membrane proteins, failed to activate NF-kB and/or to induce IL6 secretion. Interestingly, transfection of the LMP1 homologues from the simian EBV naturally infecting baboons (Cercopithicine herpesvirus 12, Herpesvirus papio) and rhesus monkeys (Cercopithicine herpesvirus 15) (Franken et al., 1996) into SV-AR-K cells induced both NF-kB and IL6 at levels similar to the B95.8 prototype of LMP1 used in this study (data not shown).
Further evidence for the involvement of NF-kB in LMP1-mediated activation of IL6 is underlined by experiments using NF-kB inhibitors. Thus, treatment of LMP1-transfected SV-AR-K cells with non-toxic concentrations of D609, a xanthogenate compound which has been shown to inhibit translocation of NFkB to the nucleus (Schutze et al., 1992) , partially blocked LMP1-mediated NF-kB activity (Figure 2d , left panel) and decreased release of IL6 by 60 ± 70% when compared to control LMP1-expressing cells ( Figure 2D, right panel) . The eects of D609 on NFkB activation were veri®ed by EMSA. Similar results were obtained when LMP1-transfected SV-AR-K cells were treated with the NF-kB inhibitor PCDA. In addition, co-transfection of pSG5-LMP1 and the IkB- . The speci®city of the binding was determined by competition experiments in which nuclear extracts isolated from SV40-transformed keratinocytes at 48 h post-transfection with pSG5LMP1 were analysed in the presence of 50-fold excess of unlabelled kB-probe or an unrelated AP1 probe (E3AP1) (right panel, lanes 1 ± 4). The composition of the LMP1-activated NF-kB complexes was examined by supershift analysis using antibodies raised against the p50 or p65 subunits of NF-kB or c-rel (right panel, lanes 5 ± 8). (c) Induction of IL6 RNA and protein levels in response to transient LMP1 expression. RNA isolated from SV-AR-K cells at various time points post-transfection with 2.5 mg pSG5LMP1 was subjected to RT ± PCR using primers speci®c for IL6 or GAPDH. The arrows show hybridization signals of the PCR products (left panel). Supernatants from transiently transfected SV-AR-K cultures were collected and subjected to IL6 ELISA in order to determine the levels of IL6 secretion following LMP1 expression (right panel). Data are representative of two independent experiments. (d) LMP1 mediates IL6 production via an NF-kB-dependent pathway. The metabolic inhibitor D609 reduces LMP1-mediated NF-kB activity, as determined by luciferase reporter assays (left panel). SV-AR-K cells were transfected with pSG5LMP1 and treated with 20 mg ml 71 D609 for 36 h before analysed for NF-kB activity as described in Materials and methods. Supernatants from D609-treated LMP1-transfected cells or control cultures were analysed for IL6 protein levels using an IL6 ELISA (right panel). Data shown are representative of three independent experiments and are the mean of duplicate determinations expressing vector pRcCMVIkBa reduced NF-kBmediated luciferase activity and IL6 secretion in a dose-dependent manner (data not shown), further supporting a direct role for NF-kB in LMP1-induced IL6 production.
CD40 ligation induces IL6 via an NF-kB mechanism
Previous studies have demonstrated functional similarities between CD40 ligation and LMP1 expression in terms of NF-kB activation, up-regulation of various phenotypic markers (i.e. CD23, CD54), growth stimulation of resting B-cells and inhibition of epithelial cell growth. As CD40 ligation has been shown to induce IL6 release in a number of cell systems, the contribution of NF-kB to this pathway was examined. Expression of CD40 in keratinocytes and epithelial tumour cell lines was determined by¯ow cytometric analysis using the anti-CD40 mAb G28.5. SV-AR-K keratinocytes and EJ and T47D tumour epithelial cell lines expressed high levels of CD40 whilst HeLa cells were negative for CD40 expression (Table  1) . Treatment of the above CD40-expressing cell lines with 5 mg ml 71 puri®ed CD40L or 5 mg ml 71 G28.5 mAb induced NF-kB activity in a time-dependent manner, as determined by both luciferase reporter and EMSAs (see Figure 7a and data not shown), which is in agreement with previous reports in other cell systems Hess et al., 1995) . No eect was observed with equivalent concentrations of isotypematched (IgG1) control antibody and treatment with anti-Fas mAbs failed to induce NF-kB activity. As in LMP1-mediated NF-kB activation, the NF-kB complex activated by CD40 ligation in SV40-transformed keratinocytes was found to contain p50 : p65 heterodimers, as determined by supershift experiments using anti-p50 and anti-p65 speci®c antibodies.
Treatment of SV-AR-K cells with 5 mg ml 71 CD40L induced a maximum of 2.5-fold increase in IL6 transcription and signi®cantly prompted protein secretion, as determined by RT ± PCR and ELISA respectively (see Figure 7a and data not shown). These eects were not restricted to SV40-transformed keratinocytes, as CD40 ligation in EJ and T47D cells also induced NF-kB activity and increased IL6 secretion, which is in agreement with previous reports in CD40-transfected ®broblasts and epithelial cells (Hess et al., 1995) . Interestingly, the levels of luciferase activity and IL6 release induced by CD40 ligation were always signi®cantly lower than those following LMP1 expression. This was not dependent on the amount of CD40L or G28.5 mAb used, as concentrations up to 15 mg ml 71 of either CD40L or G28.5 mAb also failed to reach levels of activation similar to those observed with LMP1.
The role of NF-kB in mediating IL6 secretion in response to CD40 ligation is supported by experiments in which CD40-negative HeLa cells were transfected with a CD40-expression vector or with a CD40 mutant (Thr
254
?Ala: designated CD40 A ) which is de®cient in NF-kB activation in response to CD40 ligation . Stable transfectants resistant to geneticin G418 were generated and examined for CD40 expression using FACS analysis. Selected CD40 or CD40
A clones (Table 1) were treated with 5 mg ml 71 CD40L, G28.5 or control antibody and NF-kB activity was assessed by luciferase reporter assays. In representative experiments it was found that engage- the inhibition of NF-kB lead to a signi®cant reduction in the levels of CD40-mediated IL6 secretion (data not shown).
A core TRAF binding PxQxT motif exists in both LMP1 and CD40
The above results indicate that a common signalling pathway exists between CD40 and LMP1 in epithelial cells. Previous reports, focused predominantly in B cells, identi®ed a minimal PxQxT motif in the cytoplasmic tail of CD40 which is important for TRAF binding. A Thr
?Ala mutation (PxQxT? PxQxA) disrupts the motif, preventing TRAF binding to the CD40 tail and thereby abrogating subsequent signalling (Inui et al., 1990; Hu et al., 1994; Rothe et al., 1995; Sarma et al., 1995) . In agreement with these data, both TRAF2 and TRAF3 are expressed in epithelial cell lines (Figure 4a ) and expression of a Thr
?Ala CD40 mutant in HeLa cervical epithelial cells abolishes CD40-mediated NF-kB activation and IL6 release.
Recent reports have also identi®ed TRAFs interacting with the cytoplasmic C-terminus of LMP1. The TRAF binding domain of LMP1 was mapped and located in the membrane proximal 44 amino acids of the carboxyl terminus (amino acids 187 ± 231) (Mosialos et al., 1995; Kaye et al., 1996; . Alignment of the CD40 region around Thr 254 with the LMP1 amino acids 187 ± 231 revealed a common PxQxT sequence (Figure 4b) . No other sequence similarities were identi®ed.
Two distinct domains in the carboxy-terminus of LMP1 mediate NF-kB activation and IL6 secretion in epithelial cells
Previous studies have identi®ed two domains in the carboxy-terminus of LMP1 which are important for NF-kB activation, the C-terminal activating region-1 (CTAR-1, residues 194 ± 232) and CTAR-2 (residues 351 ± 386, Figure 4c ) (Huen et al., 1995) . CTAR-1 overlaps with the proximal 44 amino acid domain of the carboxyl terminus which binds TRAFs (aa 187 ± 231). In order to de®ne a role for CTAR-1 and CTAR-2 in NF-kB activation and IL6 production in epithelial cells, a number of deletion and point mutations of LMP1 were constructed and are depicted in Figure 5a . Transient transfection of LMP1 gene constructs into SV-AR-K cells resulted in approximately similar levels of expression of truncated or mutated LMP1 proteins, as determined by Western blot analysis using the CS.1-4 anti-LMP1 mAbs (Figure 5b ). RT ± PCR, using primers speci®c for the N-terminus of LMP1 was performed to verify equal levels of expression between wild type LMP1 and deletion mutants D [194 ± 386] . This result is surprising as a similar mutation on the PxQxT motif of CD40 completely abolished CD40 signalling. Although the reason(s) for this discrepancy are unclear, it may be that residues adjacent to PxQxT motif to LMP1 may strongly in¯uence the three dimensional structure of the motif and therefore TRAF binding and signalling. This could also explain the reduction in NF-kB activation observed with the deletion mutant D[214 ± 232] which removes some of the adjacent residues of the TRAF binding domain. To determine the generality of these observations, all of the above experiments were repeated in HeLa cells and gave similar results (data not shown).
LMP1 induces NF-kB activation and IL6 secretion via a mechanism involving TRAFs
In order to determine a direct role for TRAFs in mediating LMP1-induced NF-kB activation and IL6 secretion in epithelial cells, SV-AR-K cells were transiently co-transfected with pSG5-LMP1 or control vector in the presence or absence of increasing amounts of plasmids expressing dominant negative forms of TRAF2 (TRAF2DN) or TRAF3 (TRAF3DN). The TRAF2DN consists of an amino-terminal RING ®nger deletion mutant of TRAF2 (D[6 ± 86]) which, when expressed, inhibits NF-kB activation mediated by TNFRII or CD40. The TRAF3DN construct consists of a truncated C-terminal TRAF3 (D[345 ± 568]) which has been shown to abrogate CD40-mediated upregulation of CD23 in Ramos B-cells by an unde®ned mechanism. The eects of these dominant negative forms of TRAF2 and TRAF3 on LMP1-mediated activation of NF-kB were evaluated by luciferase reporter assays and EMSAs. Expression of TRAF2DN was found to signi®cantly reduce luciferase activity mediated by expression of full length LMP1 (Figure 6a, left panel) . Interestingly, over-expression of TRAF3DN also inhibited NF-kB activity (Figure 6a,  left panel) . These results were veri®ed by EMSA (data not shown). In addition, the levels of expression of IL6 were in¯uenced in a similar way with both TRAF2DN and TRAF3DN inhibiting LMP1-induced IL6 secretion (Figure 6a, right panel) . Over-expression of TRAF2DN or TRAF3DN did not in¯uence LMP1 expression in the transfected SV-AR-K cells as determined using Western blot analysis (data not shown). Similar results were obtained in HeLa cells.
As the TRAF binding domain of LMP1 is located within CTAR-1, the eect of TRAF2DN and TRAF3DN on the NF-kB activity mediated by the LMP1 deletion mutant D[332 ± 386] was also examined. As expected, both dominant negative TRAFs significantly inhibited NF-kB activation from this LMP1 deletion (Figure 6b) . Surprisingly, however, whilst over-expression of TRAF3DN had no eect on NFkB induced by the LMP1 deletion mutant D[187 ± 351], which contains only the CTAR-2 region, TRAF2DN substantially inhibited the eect (Figure 6b ). This result was unexpected, as no evidence exists for direct association of TRAF2 with the extreme C-terminus of LMP1 . These observations are supported by experiments in which A20 was overexpressed in SV-AR-K cells in the presence of full length LMP1 or of the LMP1 deletion mutants D [332 ± 386] or D[187 ± 351]. A20 is an anti-apoptotic RING ®nger protein which has been recently shown to interact with the C-terminal domain of TRAF2 and to inhibit TRAF2-mediated NF-kB activation upon ligation of CD40 or TNFRII (Song et al., 1996) . Interestingly, expression of A20 was found to inhibit NF-kB activation mediated by wild type Over-expression of full length TRAF2 but not TRAF1 or TRAF3 has been shown to activate directly NF-kB in 293 cells. In agreement with these reports, expression of TRAF1 or TRAF3 in SV-AR-K keratinocytes or HeLa cells had no eect on NF-kB levels. However, expression of TRAF2 under an SV40 promoter failed to induce NF-kB to the previously reported extent. Thus, TRAF2 over-expression in SV-AR-K, HeLa or EJ cells induced a small (2 ± 3-fold) increase in NF-kB activity (data not shown). This was not due to transfection of sub-optimal amounts of TRAF2-expressing plasmid, as similar levels of induction were observed across a wide range of plasmid concentrations (0.1, 1, 2.5 or 10 mg DNA). It is possible that the levels of TRAF2 expression may be critical for NF-kB activation; relatively low expression of TRAF2 has been reported to induce only small increase in NF-kB activity (Cheng and Baltimore, 1996) . Alternatively, it is possible that the eect(s) of TRAF2 expression on the levels of NF-kB activation may be cell type-dependent. When SV-AR-K cells were co-transfected with pSG5TRAF2 and LMP1, only a small increase in LMP1-mediated NF-kB activity was observed whilst expression of TRAF1 or TRAF3 in the presence of LMP1 induced a signi®cant decrease in NF-kB activity (51[+5]% and 13.5[+2.5]% respectively) and IL6 secretion (data not shown).
CD40 ligation induces NF-kB activation and IL6 secretion via a mechanism involving TRAFs
Transient expression of TRAF2DN in SV-AR-K cells decreased CD40-mediated NF-kB activity in a concentration-dependent manner, as determined by both luciferase reporter and EMSAs (Figure 7 , left panel and data not shown), which is in agreement with previous reports in 293 and CT6 cells (Rothe et al., 1995) . This decrease in NF-kB activity was accompanied by inhibition of IL6 secretion (Figure 7 , right panel). Interestingly, over-expression of TRAF3DN was also found to inhibit CD40-mediated NF-kB activity and IL6 production, although to a lesser (Figure 7 ). The eect of these dominant negative mutants of TRAF2 or TRAF3 on CD40-induced IL6 secretion (Figure 7 , right panel) was relatively minor compared to the observed eect of NF-kB-dependent luciferase activity. This dierence could be explained by the fact that whilst the majority of SV-AR-K cells express CD40, only a percentage of them can be eectively transiently transfected with TRAF2DN or TRAF3DN plasmid. Over-expression of TRAF2DN or TRAF3DN had no eect on the levels of NF-kB activation induced by IL-1 (data not shown), which underlines the speci®city of the eect.
High levels of IL6 in¯uence epithelial cell growth
Previous studies have implicated IL6 as an important regulator of cell growth in a variety of dierent cell types. Thus, exogenous IL6 has been shown to inhibit or promote proliferation depending on the nature of the responsive target cells and possibly other additional factors. As both LMP1 expression and CD40 ligation induce IL6 secretion and growth inhibition, a role for IL6 in mediating the growth-inhibitory eects of CD40 and LMP1 was determined. SV-AR-K were treated with 100, 500 or 1000 pg ml 71 rhIL6 for 72 h and cell growth was then assessed by [ 3 H]thymidine incorporation. As depicted in Figure 8 , addition of exogenous IL6 signi®cantly decreased proliferation; however the levels of IL6-mediated growth inhibition were lower than those observed in response to CD40 stimulation. In addition, treatment of T47D cells with IL6 inhibited cell growth and signi®cantly potentiated the antiproliferative eect of CD40 ligation (data not shown).
Discussion
In this study we describe a novel function of LMP1 in epithelial cells. We have shown that stable or transient LMP1 expression in SV40-transformed keratinocytes and in epithelial tumour cell lines of bladder, breast, ovarian and cervical origin induces signi®cant levels of IL6 expression and secretion. This phenomenon is also observed following CD40 ligation adding further support to the contention that LMP1 and CD40 share common functions and overlapping signalling pathways (Eliopoulos et al., 1996) . Thus, both LMP1 expression and CD40 ligation in epithelial cells result in rapid nuclear translocation of NF-kB, activation of NF-kB-responsive reporter constructs, transactivation of the IL6 gene and subsequent secretion of IL6 into the growth medium. The NF-kB complex implicated in CD40 or LMP1 signalling contains p50 : p65 heterodimers, as determined by competition experiments in electrophoretic mobility shift assays. Evidence substantiating the hypothesis that LMP1 and CD40-mediated IL6 production is dependent on nuclear translocation of NF-kB was provided by demonstrating that the suppression of NF-kB activation by either the metabolic inhibitor D609 or the anti-oxidant PCDA decreased CD40L and LMP1-mediated IL6 secretion. In addition, over-expression of IkB inhibited both NF-kB transcriptional activity and IL6 secretion in response to LMP1 expression or CD40-CD40L interaction. Interestingly, the other EBV-encoded latent membrane proteins, LMP2A and LMP2B, did not in¯uence NF-kB or IL6 levels suggesting a unique role for LMP1 in mediating these eects.
The proximal signalling events leading to NF-kB activation upon CD40 stimulation or LMP1 expression are unclear. However, the recent identi®cation of TRAF proteins has provided insight into the mechanism of NF-kB activation through the TNFreceptor family. Thus, TRAF2 is acquired for CD40 as well as TNFRI and TNFRII-mediated NF-kB activation and TRAF2 over-expression is sucient to activate NF-kB-responsive promoters (Rothe et al., 1995; Hsu et al., 1996) . TRAF3 also associates with the cytoplasmic tail of CD40 through a TRAF binding domain which is characterised by a PxQxT core sequence (aa 250 ± 254) essential for interaction. Indeed, a Thr 254 ?Ala mutation diminishes association of TRAFs with CD40 and blocks CD40-mediated NF-kB activation (Inui et al., 1990; Hu et al., 1994; Rothe et al., 1995) . In agreement with these reports, expression of the above CD40 mutant in HeLa cells abrogated NF-kB activity and IL6 secretion in response to CD40 ligation. Interestingly, a PxQxT motif also exists in the membrane proximal 44 amino acids of the carboxyl terminus of LMP1 (aa 204 ± 208) which are required for growth transformation mediated by LMP1. This region, named CTAR1, binds TRAF1, TRAF2 and TRAF3 and mediates NFkB activation (Huen et al., 1995; Mosialos et al., 1995; Kaye et al., 1996; Devergne et al., 1996) . CTAR2 (residues 351 ± 386) can independently activate NF-kB but does not associate with TRAFs . Transient expression of LMP1 mutants lacking either CTAR1 (D[187 ± 351] ) or CTAR2 (D[332 ± 386]) activated NF-kB and IL6 secretion in SV-40 transformed keratinocytes and HeLa cells. The levels of activation in SV-AR-K cells were similar for these two domains and accounted for approximately 30% of the activity of the wild type LMP1, whilst in B and T cells the contribution of CTAR2 is more prominent than that of CTAR1 (Huen et al., 1995; Mitchell and Sudgen, 1995; Devergne et al., 1996) . To assess the signi®cance of the PxQxT motif of LMP1 in the regulation of IL6 expression, we have generated a number of additional deletion mutants which remove the TRAF-binding core sequence and/or adjacent residues from full length LMP1. Removal of the PxQxT motif (D[187 ± 212]) reduced NF-kB activity and IL6 secretion to levels similar to those observed with the deletion mutant D[332 ± 386] which contains only the CTAR1 region. These results suggest that CTAR1 mediates NF-kB activity and IL6 production via a TRAF-dependent mechanism. This hypothesis is supported by the observation that a triple point mutations which disrupts the PxQxT motif of LMP1D [332 ± 386] ?A) abrogates NF-kB activity by the proximal C-terminus of LMP1. However, our results also suggest that residues surrounding the PxQxT core sequence may in¯uence CTAR1 signalling. Thus, whilst deletion of aa 187 ± 193 had no eect on NF-kB activity and IL6 secretion, removal of residues 214 ± 232 partially inhibited the above eects and a T
208
?A mutation did not abrogate CTAR1 signalling. Recent studies have also indicated that a PxQxT motif is necessary but not sucient for TRAF binding on the cytoplasmic tail of CD40. Thus, a GST protein fused to 16 aa from the CD40 cytoplasmic tail including the PxQxT core sequence failed to bind TRAF3 in vitro and a Thr 383 ?Ala mutation in rhesus LMP1 only partly inhibited TRAF3 binding (Franken et al., 1996) . It is likely that the three dimensional structure of the motif is in¯uenced by surrounding sequences and may aect the speci®cities of TRAF family members in receptor binding. In this context it is interesting that TRAF2 binds LMP1 only weakly but associates strongly with CD40 (Rothe et al., 1995; Devergne et al., 1996) and that several PxQxT sites in the rhesus or baboon LMP1s do not bind TRAF3 (Franken et al., 1996) .
Our results also suggest that TRAF molecules regulate LMP1 and CD40-dependent NF-kB activation in epithelial cells. Thus, over-expression of dominant negative mutants of TRAF2 and TRAF3 signi®cantly inhibited NF-kB activation in response to CD40 ligation or LMP1 expression. In addition to the eects of dominant negative TRAFs, over-expression of full length TRAF3 inhibited LMP1 and CD40-mediated NF-kB activation and similar results were observed upon transfection of TRAF1. These observations suggest that TRAF1 and TRAF3 may compete with TRAF2 for occupancy of the TRAF binding site of LMP1 or CD40. Displacement of TRAF2 could then explain the observed inhibition of NF-kB activity by TRAF1 or TRAF3 in LMP1-transfected or CD40L-treated cells. A similar TRAF1 and TRAF3-mediated phenomenon has been recently described in CD40-transfected 293 cells (Rothe et al., 1995) . As TRAF3 binds only to the proximal 44 aa of LMP1 (CTAR1) (Mosialos et al., 1995) , expression of TRAF3DN had no eect on the NF-kB activity induced by the extreme carboxy-terminus of the protein (CTAR2). Interestingly, however, whilst TRAF2 associates directly only with CTAR1 , over-expression of TRAF2DN partially blocked NF-kB induced by both eector domains of LMP1. Although a weak interaction of TRAF2 with a PxQxS motif near the end of CTAR2 cannot be excluded, an indirect association is also possible.
In accordance with a role for NF-kB in regulation of IL6, over-expression of dominant negative TRAF2 or TRAF3 inhibited LMP1 and CD40-mediated IL6 secretion suggesting that the signalling pathways leading to IL6 production involve TRAFs. Consistent with this theory is the observation that ectopic expression of A20 decreases CD40 and LMP1-mediated NF-kB activation and IL6 secretion in SV-AR-K and HeLa cells. A20 is an anti-apoptotic RING ®nger protein which is under dominant NF-kB control and is up-regulated in response to TNFRI, CD40 or LMP1 signalling (Laherty et al., 1992; Sarma et al., 1995) . A20 has been recently shown to associate with TRAF2 in yeast two-hybrid assays and to block NFkB activity induced by CD40 over-expression or TNF treatment (JaaÈ ttela et al., 1996; Song et al., 1996) . The ability of A20 to block NF-kB activation is however not limited to TRAF2-mediated pathways as A20 is able to inhibit IL-1-induced NF-kB even though this pathway does not involve TRAF2 (Song et al., 1996) . Our results demonstrate that A20 expression in epithelial cells inhibits NF-kB activity and IL6 production induced by LMP1 and that this eect is more pronounced than that of TRAF2DN, suggesting the existence of alternative pathways mediating LMP1-dependent NF-kB activation.
The stimulation of IL6 secretion by CD40 ligation has previously been reported. The ability of the CD40 pathway to induce IL6 secretion in epithelial cells and the eects of IL6 on epithelial cell growth suggest that the growth-regulatory properties of CD40 signalling may be partly mediated by this cytokine. Interestingly, IL6 has been shown to inhibit the growth of certain carcinoma and leukemic cell lines (Clark & Shu, 1990; Chen et al., 1991; Takizawa et al., 1993) whilst normal human keratinocytes cultured in the absence of growth factors can be induced to proliferate in response to low concentrations of IL6 (Grossman et al., 1989) . This suggests that the epithelial cell phenotype and dierentiation status may aect the responsiveness of the cells to IL6 and thus to the consequences of CD40 ligation. This may be particularly relevant to the contribution of LMP1 to the transformation process leading to the development of NPC; the basal phenotype of NPC cells may confer a proliferative eect upon either LMP1 expression or CD40 stimulation in this cellular environment. Supporting this contention is the proposed role of IL6 in psoriasis, a disease characterised by keratinocyte hyperproliferation and altered dierentiation (Grossman et al., 1989; Stadnyk, 1994) . In this condition increased production of IL6 predominantly from basal keratinocytes (where CD40 is also expressed, Young et al., 1989) is observed and this is thought to be directly related to the epidermal hyperplasia characteristic of psoriatic skin.
IL6 has also been shown to induce ICAM1 (CD54) expression in carcinoma cell lines (Hutchins and Steel, 1994) and may be part of the mechanisms by which CD40 and LMP1 up-regulate this phenotypic marker. Thus, we have found that treatment of T47D cells which express relatively low levels of ICAM1, with 500 or 1000 pg ml 71 rhIL6 induces a signi®cant increase in ICAM1 levels (data not shown). Expression of CD40 or Fas was not in¯uenced by IL6 treatment.
Interestingly, conditioned supernatant from LMP1-transfected but not LMP1-D [194 ± 386] or vectortransfected SV-AR-K cells also induced signi®cant ICAM1 expression in T47D cells whilst Fas levels remained unchanged (data not shown).
Previous work has suggested that under certain circumstances IL6 may be capable of modifying CD40 signalling. An interesting observation from these original studies is that IL6 induces phosphorylation of CD40 possibly at the important Thr 254 residue within the TRAF binding motif (Clark and Shu, 1990) . This suggests that IL6 may in¯uence CD40 and LMP1 signalling possibly by altering the anity of the TRAF interaction, an eect which may be dependent on the cell phenotype. This current study extends our previous work implicating TRAF3 in the CD40 and LMP1-induced growth inhibition of epithelial cells (Eliopoulos et al., 1996) . Future studies examining the role of NFkB in modulating epithelial cell growth are of particular interest given the results of recent work suggesting that NF-kB activation is important in the control of apoptosis (Beg and Baltimore, 1996; Liu et al., 1996; Van Antwerp et al., 1996; Wang et al., 1996) .
Materials and methods

Cell lines and reagents
The human bladder carcinoma cell line EJ, the cervical HeLa and the ovarian A2780 were continuously maintained in RPMI 1640 medium (Gibco, UK) supplemented with 10% fetal calf serum (FCS) and 2 mM glutamine. T47D breast carcinoma cells were cultured in Dulbecco's Modi®ed Eagle's (DME) medium supplemented with 10% fetal calf serum (FCS) and 2 mM glutamine. SV40-transformed human keratinocytes (SV-AR-K) were grown in Joklics/8% FCS in the presence of 2 mM glutamine and 0.4 mg/ml hydrocortisone (Gibco).
Human recombinant interleukin1a (rhIL1) and interleukin 6 (rhIL6) were purchased from R&D Systems. The xanthogenate compound D609 (tricyclodecan-9-yl-xanthogenate potassium) which has been shown to inhibit nuclear translocation of NF-kB (Schutze et al., 1992) and the antioxidant and potent NF-kB inhibitor 1-pyrrolidinecarbodithioic acid (PCDA) were purchased from Calbiochem (LaJolla, USA) and were dissolved in growth medium immediately before use. Anti-CD40 mAb G28.5 was kindly provided by Prof J Gordon, Department of Immunology, University of Birmingham Medical School, Birmingham, UK). Anti-CD54 (ICAM1) and Fas UB2 and CH11 mAbs were purchased from SeroTec, UK and Immunotech, France respectively. HPLC-puri®ed CD40L trimer was kindly provided by Dr A Armitage, Immunex Research and Development Corporation, Seattle, USA.
DNA constructs and transfections
HeLa cells were co-transfected with the plasmid pCDjSV2 conferring resistance to geneticin G418 and the CD40-expressing vector CDM8/CD40 (Stamenkovic et al., 1989) or with a mutant CD40 (Thr 254 ?Ala: designated CD40 A ) expressing construct (kindly provided by Dr Vishva Dixit, Dept of Pathology, University of Michigan Medical School, Michigan, USA) using the calcium phosphate technique and stable transfectants were selected. Similarly, EJ, SCC12F and A2780 cells were transfected with the LMP1 expression vector pSV2.gpt.MTLM and stable clones, resistant to mycophenolic acid were isolated.
Transient transfections in SV-AR-K, HeLa and EJ cells were performed using a modi®cation of DEAE-dextran method which gives high transfection eciency (Gonzalez and Joly, 1995) , as previously described (Eliopoulos et al., 1996) . T47D cells were transfected using a standard calcium phosphate technique.
The TRAF1 (EBI6), TRAF2, TRAF3 (LAP1) and dominant negative TRAF2 and TRAF3-expressing constructs (Mosialos et al., 1995; Kaye et al., 1996) 
Site-directed mutagenesis of LMP1
Point mutations in the LMP1 deletion construct D[332 ± 386] were introduced by site directed mutagenesis using the QuikChange TM site-directed mutagenesis kit of Stratagene. The mutated oligonucleotide primers used were: 5'-GCACCCTCAACAAGCTGCCGATGATTCTGG-3' and its complementary oligo to generate a Thr 208 ?Ala mutation (construct pSG5LMP1D [332 ± 386] A ) and 5'-CC-TCCCGCACGCTCAAGCAGCTGCCGATGA-3' and its complementary primer to generate a triple Pro 204 ?Ala, GIn 206 ?Ala and Thr 208 ?Ala mutation (construct pSG5LMP1D [332 ± 386] AAA ; underlined letters represent mutated bases which generate amino acid changes). The presence of the above point mutations was veri®ed by sequencing.
Immuno¯uorescence studies
Expression of CD40 on epithelial cells and on CD40-transfected HeLa cells was determined by¯ow cytometry as previously described (Young et al., 1989; Dawson et al., 1990) . Brie¯y, for the¯ow cytometric analysis of CD40 expression, cells were trypsinised and stained with 1 mg/ml of either anti-CD40 G28.5 mAb (Clark & Ledbetter, 1986; Katira et al., 1995) or of the control anti-CD23 MHM6 mAb (Dawson et al., 1990 ) for 1 h, followed by a 30 min incubation with 1 : 50 dilution of FITC-conjugated goat anti-mouse IgG (Sigma, UK). The cells were then washed in PBS, ®xed with 2% paraformaldehyde and analysed using a FACScan (Becton Dickinson). A similar approach was used for the¯ow cytometric determination of Fas and CD54 (ICAM) expression.
Protein extraction and immunoblotting
For the preparation of protein extracts and immunoblotting, a standard method was used as previously described (Eliopoulos et al., 1995) . One hundred mg of total cell lysates were analysed on a 10% gel and LMP1 expression was detected with the anti-LMP1 mAbs CS.1-4. Immune complexes were detected with [
125 I]Protein A (Amersham, UK) after incubation with rabbit anti-mouse IgG (Sigma, UK).
Interleukin 6 (IL6) ELISA
The presence of IL6 protein in the supernatant of cultured tumour cells was quantitated by ELISA. Approximately 5 ± 7610 4 cells were plated out onto a 24 well plate, supernatants were collected at various time points following transfection and/or CD40 ligation and analysed using the Pelikine human IL6 ELISA kit (CLB, Netherlands). Brie¯y, supernatants or recombinant human IL6 standards were applied in duplicate to Maxisorp plates coated with anti-IL6 mAb and incubated for 1 h at room temperature. The plates were then washed with PBS-0.005% Tween-20 and incubated for an additional 1 h with 100 ml of biotinylated anti-IL6 antibody in each well. Excess antibody was removed by washing, followed by addition of horseradish peroxidase (HRP)-conjugated streptavidin and incubation for 30 min at room temperature. After removal of non-bound HRP conjugate, a substrate solution was added to the wells and the absorbance of the coloured product was recorded 30 min later at 450 nm in an ELISA reader. The lower detection level of this ELISA varies between 0.2 and 0.4 pg ml 71 .
RNA extraction and Northern blot analysis
Preparation of total RNA and Northern blot analysis were performed as previously described (Eliopoulos et al., 1995) . For the detection of A20 expression in transiently transfected cells, a 0.6 kb probe was generated by PCR, using the A20-expression vector pJDM.A20.1(+) (kindly provided by Dr Vishva Dixit) as template and labelled using the Random Primed kit of Boehringer. The A20-speci®c primers used were: 5'-TGAGCAATATGCGGAAAGCT-3' (A20-Forward) and 5'-CTGAAATGACAATGATTG-3' (A20-Reverse). As positive control for A20 expression, RNA for cycloheximide and TNFa-treated EJ cells was used. A rat GADPH cDNA (gift from Prof J Neil, University of Glasgow, Glasgow, UK) was also used to monitor equal loading and transfer eciency.
RT ± PCR
Two mg of total RNA, isolated as described above, were treated with 0.2 mg ml 71 DNase I (Gibco) for 15 min at room temperature. Oligo dT primers (Gibco) were then used to prime cDNA synthesis with Superscript Reverse Transcriptase (Gibco) and 1 mM dNTP (Pharmacia) by incubation at 428C for 1 h. Following heat inactivation at 708C for 15 min, the reaction was ®nally incubated with RNase H (Gibco) at 378C for 20 min in a ®nal volume of 20 ml. Two ml of the synthesised cDNA was used for PCR.
The TRAF2 cDNA ampli®cation was carried out in a 30-cycle PCR reaction with denaturation at 948C for 45 s, annealing at 508C for 60 s, extention at 728C for 60 s and ®nal extention at 728C for 5 min in a thermal cycler (Perkin Elmer Cetus). The sequences of the primers used were: 5'-AAAGCGTCAGGAAGCCGTAG-3' (TRAF2-Forward) and 5'-CCGCACATAGGAATTCTTGG-3' (TRAF2-Reverse), which generates a 369 bp fragment. The TRAF3 cDNA ampli®cation was done at similar conditions using the following primers: 5'-AAGCAGACAGCATGAAGAGCA-3' (TRAF3-Forward) and 5'-GCTTGAATGCATCTCC-CAAATG-3' (TRAF3-Reverse), which generate a 503 bp fragment.
To monitor IL6 expression in LMP1-transfected or CD40L-treated SVK cells, a semi-quantitative RT ± PCR was performed. The cDNA ampli®cation was carried out under the following conditions: denaturating at 948C for 45 s, annealing at 428C for 30 s, extention at 728C for 60 s and ®nal extention at 728C for 5 min. The primers used were: 5'-ATGTAGCCGCCCCACACAGA-3' (IL6-Forward) and 5'-CCATCCATCTTTTTCAGCCATC-3' (IL6-Reverse) which generate a 171 bp fragment. Ampli®cation for GADPH was simultaneously performed to normalize for IL6 expression. This PCR was carried out under the following conditions: denaturation at 948C for 45 s, annealing at 668C for 30 s, extention at 728C for 50 s and ®nal extention at 728C for 5 min and the primers used were: 5'-CCACCCATGG-CAAATTCCATGGCA-3' (GADPH-Forward) and 5'-TCTAGACGGCAGGTCAGGTCCACC-3' (GAPDH-Reverse), which give a 597 bp fragment. The number of PCR cycles used was 24, as determined by pilot experiments designed to assess the linear range of amplication for IL6 and GADPH. All appropriate control experiments were performed, including ampli®cation of DNase I-treated RNA samples for detection of residual DNA contamination and ampli®cation of water-control samples.
PCR products in each case were analysed on a 1.5% agarose gel, transferred to a Hybond-N + membrane and hybridized with the following gene-speci®c oligo-probes: 5'-TACTTGAATGGCGACGGCAC-3' (TRAF2-Probe), 5'-AGTGACACTCATGCTGATGGA-3 (TRAF3-Probe), 5'-ACAAACAAATTCGGTACATCC-3' (IL6-Probe) and 5'-TGAGAAGTATGACAACAGCC-3' (GAPDH-Probe). IL6 versus GAPDH-speci®c hybridisation signals were quanti®ed on a Molecular Dynamics phosphorimager.
Luciferase and b-galactosidase reporter assays NF-kB activity was determined by quantitating the Luciferase expressed from the transfected NF-kB reporter plasmid kBConALuc. This construct comprises the P pyralis luciferase gene cloned downstream of minimal conalbumin promoter into which three kB elements derived from the immunoglobulin kappa chain enhancer are inserted (Arenzana-Seisdedos et al., 1993) and was kindly provided by Dr F Arenzana-Seisdedos (Institute Pasteur, Paris, France). Alternatively, an HIV-LTR luciferase reporter gene construct or its mutated version with inactivated NF-kB sites (kindly provided by Dr N Israel, Institute Pasteur, Paris, France) was used. At 36 to 40 h post-transfection, cells were washed with PBS and lysed in a buer constituting 100 mM HEPES pH 8.0, 2 mM magnesium chloride, 5 mM dithiothreitol (DTT) and 2% Triton X-100. Luciferase activity was then measured in a Berthold LB 9501 luminometer following injection of 100 ml of 0.5 mM luciferin dissolved in 30 mM glycylglycine buer (pH 8.0). Light release was integrated for 10 s. The luciferase activity in each sample was normalised for variations in transfection eciency determined by measuring b-galactosidase enzyme expressed from the cotransfected CMV-b-gal plasmid, as previously described (Eliopoulos et al., 1996) .
Electrophoretic mobility shift assays
Cell nuclei isolated by resuspending cells in a solution containing 10 mM HEPES (pH 7.9), 1.5 mM magnesium chloride, 10 mM potassium chloride, 0.5 mM (DTT) and protease inhibitors were subjected to lysis in a buer constituting 20 mM HEPES (pH 7.9), 25% glycerol, 1.5 mM magnesium chloride, 0.42 M sodium chloride, 0.2 mM EDTA, 0.5 mM (DTT) and protease inhibitors. Protein concentration of isolated nuclear extracts was determined by the Biorad protein assay, according to manufacturer's instructions (Biorad). For Electrophoretic Mobility Shift Assays (EMSA) a 29 bp HIV-kB probe (5'-GATCAGGGACTTTCCGCTGGGGACTTTCC-3', Sarma et al., 1995) was made by annealing complementary synthetic oligonucleotides and end-labelling using [g-32 P]ATP (Amersham, UK) and T4 polynucleotide kinase (Boehringer, Germany). Binding reactions containing 10 mg of nuclear protein extract, 1 mg of poly(dI-dC) (Pharmacia, Sweden), 0.1 ng of HIV-kB probe labelled to a speci®c activity of 2610 8 c.p.m./mg and binding buer (4% glycerol, 1 mM EDTA, 5 mM DTT, 0.01 M Tris.HCl pH 7.5 and 5 mM KCl) in a volume of 20 ml were incubated for 30 min at room temperature and then resolved by electrophoresis through a 5% polyacrylamide gel in a 0.556TBE buer. Gels were then dried and exposed to X-ray ®lm for autoradiography (Kodak). In supershift or depletion experiments, nuclear extracts were pre-incubated for 20 min with antibodies directed against the NF-kB subunits of p50 and p65 or with an anti-c-rel antibody (Santa Cruz Biotechnology) and then for further 30 min with radiolabelled probe, before subjected to EMSA as described above. The sequence of the AP-1 oligo (E3AP1) used for competition experiments is 5'-CCGAAGTTCAGATGACTAACTCAGGG-3'. 
